{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:44:59Z","timestamp":1761061499849,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12350-021-02801-9","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T18:02:24Z","timestamp":1631556144000},"page":"2336-2339","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use of mineralocorticoid receptor antagonist in ST elevation myocardial infarction"],"prefix":"10.1016","volume":"29","author":[{"given":"Muhammad H.","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron C.","family":"Gerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-021-02801-9_bib1","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1161\/01.CIR.0000134791.68010.FA","article-title":"ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction\u2014Executive summary","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02801-9_bib2","article-title":"Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction","author":"Toda","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02801-9_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","article-title":"The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study","volume":"15","author":"Pitt","year":"2001","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1007\/s12350-021-02801-9_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/hrt.2010.204149","article-title":"Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction","volume":"97","author":"Kasama","year":"2011","journal-title":"Heart"},{"key":"10.1007\/s12350-021-02801-9_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9149(91)90552-V","article-title":"Regional cardiac adrenergic function using I-123 meta-iodobenzylguanidine tomographic imaging after acute myocardial infarction","volume":"67","author":"McGhie","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-021-02801-9_bib6","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","article-title":"Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy","volume":"101","author":"Sutton","year":"2000","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02801-9_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00395-016-0556-3","article-title":"Delayed coronary reperfusion is ineffective at impeding the dynamic increase in cardiac efferent sympathetic nerve activity following myocardial ischemia","volume":"111","author":"Hall","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"10.1007\/s12350-021-02801-9_bib8","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.12659\/MSM.914105","article-title":"Cardiac sympathetic afferent denervation protects against ventricular arrhythmias by modulating cardiac sympathetic nerve activity during acute myocardial infarction","volume":"25","author":"Zhou","year":"2019","journal-title":"Med Sci Monit"},{"key":"10.1007\/s12350-021-02801-9_bib9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/jcmm.14000","article-title":"Bilateral sympathetic stellate ganglionectomy attenuates myocardial remodelling and fibrosis in a rat model of chronic volume overload","volume":"23","author":"Zhang","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1007\/s12350-021-02801-9_bib10","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1161\/01.CIR.95.8.2130","article-title":"Effects of cardiac denervation on development of heart failure and catecholamine desensitization","volume":"95","author":"Sato","year":"1997","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02801-9_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0735-1097(97)00244-1","article-title":"Reduced sympathetic innervation underlies adjacent noninfarcted region dysfunction during left ventricular remodeling","volume":"30","author":"Kramer","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02801-9_bib12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-021-02801-9_bib13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0735-1097(02)02855-3","article-title":"Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy","volume":"41","author":"Kasama","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02801-9_bib14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-021-02801-9_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s003800200042","article-title":"Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure","volume":"17","author":"Shinohara","year":"2002","journal-title":"Heart Vessels"},{"key":"10.1007\/s12350-021-02801-9_bib16","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2967\/jnumed.107.045427","article-title":"Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure","volume":"48","author":"Kasama","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-021-02801-9_bib17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/01.CIR.75.5.980","article-title":"The importance of the determination of the myocardial area at risk in the evaluation of the outcome of acute myocardial infarction in patients","volume":"75","author":"Feiring","year":"1987","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02801-9_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00392-017-1157-3","article-title":"Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: Insights from the randomized double-blind REMINDER Study","volume":"107","author":"Ferreira","year":"2018","journal-title":"Clin Res Cardiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-021-02801-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123005755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123005755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:11:46Z","timestamp":1761027106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123005755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1071358123005755"],"URL":"https:\/\/doi.org\/10.1007\/s12350-021-02801-9","relation":{},"ISSN":["1071-3581"],"issn-type":[{"type":"print","value":"1071-3581"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of mineralocorticoid receptor antagonist in ST elevation myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-021-02801-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}